Ezetimiba Vitória 10 mg Comprimido

Country: Պորտուգալիա

language: պորտուգալերեն

source: INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

active_ingredient:

Ezetimiba

MAH:

Faes Farma Portugal, S.A.

ATC_code:

C10AX09

INN:

Ezetimibe

dosage:

10 mg

pharmaceutical_form:

Comprimido

composition:

Ezetimiba 10 mg

administration_route:

Via oral

units_in_package:

Blister 28 unidade(s)

class:

3.7 - Antidislipidémicos

prescription_type:

MSRM

therapeutic_group:

Genérico

therapeutic_area:

ezetimibe

therapeutic_indication:

Duração do Tratamento: Longa Duração

leaflet_short:

Número de Registo: 5762869 CNPEM: 50104675 CHNM: 10041440 Comercializado

authorization_status:

Autorizado

authorization_date:

2018-11-27

PIL

$3529$'2(0

,1)$50('


)ROKHWRLQIRUPDWLYR,QIRUPD©¥RSDUDRGRHQWH
(]HWLPLED9LWµULDPJ&RPSULPLGRV
(]HWLPLED
/HLDFRPDWHQ©¥RWRGRHVWHIROKHWRDQWHVGHFRPH©DUDWRPDUHVWHPHGLFDPHQWRSRLV
FRQW«PLQIRUPD©¥RLPSRUWDQWHSDUDVL
&RQVHUYHHVWHIROKHWR3RGHWHUQHFHVVLGDGHGHROHUQRYDPHQWH
&DVRDLQGDWHQKDG¼YLGDVIDOHFRPRVHXP«GLFRRXIDUPDF¬XWLFR
(VWHPHGLFDPHQWRIRLUHFHLWDGRDSHQDVSDUDVL1¥RGHYHG£ORDRXWURV2
PHGLFDPHQWRSRGHVHUOKHVSUHMXGLFLDOPHVPRTXHDSUHVHQWHPRVPHVPRVVLQDLVGH
GRHQ©D
6HWLYHUTXDLVTXHUHIHLWRVLQGHVHM£YHLVLQFOXLQGRSRVV¯YHLVHIHLWRVLQGHVHM£YHLVQ¥R
LQGLFDGRVQHVWHIROKHWRIDOHFRPRVHXP«GLFRRXIDUPDF¬XWLFR9HUVHF©¥R
2TXHFRQW«PHVWHIROKHWR
2TXH«(]HWLPLED9LWµULDHSDUDTXH«XWLOL]DGR
2TXHSUHFLVDGHVDEHUDQWHVGHWRPDU(]HWLPLED9LWµULD
&RPRWRPDU(]HWLPLED9LWµULD
(IHLWRVLQGHVHM£YHLVSRVV¯YHLV
&RPRFRQVHUYDU(]HWLPLED9LWµULD
&RQWH¼GRGDHPEDODJHPHRXWUDVLQIRUPD©·HV

2TXH«(]HWLPLED9LWµULDHSDUDTXH«XWLOL]DGR
$3529$'2(0

,1)$50('


(]HWLPLED9LWµULD«XPPHGLFDPHQWRSDUDEDL[DUYDORUHVHOHYDGRVGHFROHVWHUROQR
VDQJXH
(]HWLPLED9LWµULDEDL[DRVYDORUHVGHFROHVWHUROWRWDOGRFROHVWHUROSUHMXGLFLDOFROHVWHURO
/'/HGDVVXEVW¤QFLDVJRUGDVQRVDQJXHFKDPDGDVWULJOLF«ULGRV$O«PGLVVRR
(]HWLPLED9LWµULDDXPHQWDRVYDORUHVGHFROHVWHUROEHQ«ILFRFROHVWHURO+'/
$H]HWLPLEDDVXEVW¤QFLDDWLYDGH(]HWLPLED9LWµULDDWXDUHGX]LQGRRFROHVWHUROTXH«
DEVRUYLGRQRVHXWUDWRGLJHVWLYR
2HIHLWRGHUHGX©¥RGRFROHVWHUROSHOR(]HWLPLED9LWµULD«DGLFLRQDODRGDVHVWDWLQDVXP
JUXSRGHPHGLFDPHQWRVTXHUHGX]RFROHVWHUROTXHRVHXRUJDQLVPRSURGX]
2FROHVWHURO«XPDGDVY£ULDVVXEVW¤QFLDVJRUGDVHQFRQWUDGDVQDFRUUHQWHVDQJX¯QHD
2VHXFROHVWHUROWRWDO«FRQVWLWX¯GRVREUHWXGRSRUFROHVWHURO/'/H+'/
2FROHVWHURO/'/«FRQVLGHUDGRFRPRFROHVWHUROSUHMXGLFLDOSRUTXHVHSRGHDFXP

SPC

$3529$'2(0

,1)$50('


5(6802'$6&$5$&7(567,&$6'20(',&$0(172

120('20(',&$0(172
(]HWLPLED9LWµULDPJ&RPSULPLGRV

&20326,‰…248$/,7$7,9$(48$17,7$7,9$
&DGDFRPSULPLGRFRQW«PPJGHH]HWLPLED
([FLSLHQWHVFRPHIHLWRFRQKHFLGR
&DGDFRPSULPLGRFRQW«PPJGHODFWRVHPRQRKLGUDWDGD
/LVWDFRPSOHWDGHH[FLSLHQWHVYHUVHF©¥R

)250$)$50$&Œ87,&$
&RPSULPLGR
&RPSULPLGRVEUDQFRVREORQJRVELVHODGRVJUDYDGRVFRPಯ(=ರQXPDGDVIDFHV

,1)250$‰—(6&/1,&$6
,QGLFD©·HVWHUDS¬XWLFDV
+LSHUFROHVWHUROHPLDSULP£ULD
(]HWLPLED9LWµULDDGPLQLVWUDGRFRQFRPLWDQWHPHQWHFRPXPLQLELGRUGDUHGXWDVHGD
+0*&R$HVWDWLQDHVW£LQGLFDGRFRPRWHUDS¬XWLFDDGMXYDQWH¢GLHWDHPGRHQWHVFRP
$3529$'2(0

,1)$50('


KLSHUFROHVWHUROHPLDSULP£ULDIDPLOLDUKHWHUR]LJµWLFDHQ¥RIDPLOLDUQ¥RFRQWURODGRVGH
IRUPDDSURSULDGDFRPXPDHVWDWLQDLVRODGDPHQWH
(]HWLPLED9LWµULDHPPRQRWHUDSLDHVW£LQGLFDGRFRPRWHUDS¬XWLFDDGMXYDQWH¢GLHWDHP
GRHQWHVFRPKLSHUFROHVWHUROHPLDSULP£ULDIDPLOLDUKHWHUR]LJµWLFDHQ¥RIDPLOLDUQRV
TXDLVDHVWDWLQD«FRQVLGHUDGDLQDSURSULDGDRXQ¥R«WROHUDGD
3UHYHQ©¥RGH(YHQWRV&DUGLRYDVFXODUHV
(]HWLPLED9LWµULDHVW£LQGLFDGRQDUHGX©¥RGRULVFRGHHYHQWRVFDUGLRYDVFXODUHVYHU
VHF©¥RHPGRHQWHVFRPGRHQ©DFRURQ£ULD'&HDQWHFHGHQWHVGHV¯QGURPH
FRURQ£ULDDJXGD6&$TXDQGRDGLFLRQDGRDXPDWHUDS¬XWLFDFRPHVWDWLQDRXLQLFLDGR
FRQFRPLWDQWHPHQWHFRPXPDHVWDWLQD
+LSHUFROHVWHUROHPLD)DPLOLDU+RPR]LJµWLFD+)+R
(]HWLPLED9LWµULDDGPLQLVWUDGRFRQFRPLWDQWHPHQWHFRPXPDHVWDWLQDHVW£LQGLFDGR
FRPRWHUDS¬XWLFDDGMXYDQWH¢GLHWDHPGRHQWHVFRP+)+R2VGRHQWHVSRGHPWDPE«P
UHFHEHUWUDWDPHQWRVDGLFLRQDLVH[DIHUHVHGH/'/

3RVRORJLDHPRGRGHDGPLQLVWUD©¥R
3RVRORJLD
2GRHQWHGHYHU£HVWDUDID]HUXPDGLHWDKLSROLSHPLDQWHDGHTXDGDGHYHQGRFRQWLQXDU
HVWDGLHWDGXUDQWHRWUDWDPHQWRFRP(]HWLPLED9LWµULD
$YLDGHDGPLQLVWUD©¥R«RUDO$GRV